ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Comprehensive Analysis of the Predictive Value of Adenylate Cyclase 4 on Clinical Significance, Prognosis, and Immunotherapy in Human Cancers.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenylate cyclase 4 (ADCY4), a member of the adenylate cyclase family, is an enzyme responsible for catalyzing the synthesis of the secondary messenger cyclic adenosine monophosphate (cAMP). Emerging evidence suggests a potential link between ADCY4 expression and the prognosis as well as biological behaviors of specific malignancies. Nevertheless, a systematic investigation into the role of ADCY4 in pan-cancer prognosis and its regulatory influence on the tumor microenvironment remains insufficient.
methodsThis study employed the HPA and GEPIA 2.0 databases to access ADCY4 expression across various human cancers. Utilizing R programming, we analyzed the relationship between ADCY4 expression and clinical characteristics, immune regulatory genes, immune checkpoint molecules, tumor microenvironment (TME) composition, tumor mutational burden (TMB), microsatellite instability (MSI) and drug sensitivity. DNA methylation levels of ADCY4 in uterine corpus endometrial carcinoma (UCEC) tissues were quantified using MethylTarget assay. Furthermore, in vitro experiments were conducted to validate ADCY4 expression patterns and to investigate its functional impact on UCEC cell proliferation and migratory capacity.
resultsAnalysis of TCGA datasets revealed a widespread downregulation of ADCY4 expression in multiple cancer types compared to corresponding normal tissues. ADCY4 expression levels demonstrated significant association with patient's prognosis, the expression of immune regulatory genes and checkpoints, and the degree of immune cell infiltration. Enrichment analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), indicated that ADCY4-related genes are predominantly involved in the cAMP signaling pathway. In UCEC, high ADCY4 expression was significantly associated with improved overall survival (OS) and disease specific survival (DSS). ADCY4 was confirmed to be downregulated in both UCEC tissues and cell lines. The MethylTarget assay indicated hypermethylation of ADCY4 in UCEC tissues relative to normal controls. Functional assays demonstrated that modulating ADCY4 expression significantly influenced cell proliferation and migration.
conclusionsOur collective findings suggest that ADCY4 holds promise as a potential prognostic biomarker and a novel target for cancer immunotherapy.
Indexed as
Identifiers
41845026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.